Literature DB >> 3101928

Vasodilator actions of TRK-100, a new prostaglandin I2 analogue.

T Akiba, M Miyazaki, N Toda.   

Abstract

TRK-100, a stable analogue of prostaglandin I2 (PGI2), relaxed isolated arteries of the dog precontracted with PGF2 alpha or K+; the relaxation was in the order of mesenteric and renal greater than coronary and femoral greater than basilar and middle cerebral arteries. The relaxation by TRK-100 was not affected by treatment with atropine, propranolol, cimetidine, aminophylline, and indomethacin, but was suppressed by diphloretin phosphate, a prostaglandin antagonist. Treatment with TRK-100 attenuated the contraction induced by PGF2 alpha and Ca2+ in mesenteric and basilar arteries previously exposed to Ca2+-free medium, but did not significantly alter the contractile response to Ca2+ in the arteries exposed to Ca2+-free medium and depolarized by excess K+. TRK-100 and nitroglycerin relaxed isolated mesenteric arteries to a similar extent; however, when continuously infused into mesenteric arteries in anaesthetized dogs, TRK-100 produced greater vasodilatation than nitroglycerin. It is concluded that TRK-100 relaxes dog mesenteric and renal arteries more than cerebral arteries; the relaxation appears to derive from interference with the release of Ca2+ from intracellular stores and with the transmembrane Ca2+ influx through a receptor-operated channel. TRK-100 may vasodilate large and small mesenteric arteries and resistance vessels to a similar extent, whereas nitroglycerin preferentially dilates the large artery.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3101928      PMCID: PMC1917240          DOI: 10.1111/j.1476-5381.1986.tb11174.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  13 in total

Review 1.  Vasodilatation of small and large arteries in hypertension.

Authors:  J A Levenson; A C Simon; M E Safar
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

2.  Modifications by stretches of the mechanical response of isolated cerebral and extracerebral arteries to vasoactive agents.

Authors:  N Toda; Y Hatano; S Hayashi
Journal:  Pflugers Arch       Date:  1978-04-25       Impact factor: 3.657

Review 3.  Role of endothelium in responses of vascular smooth muscle.

Authors:  R F Furchgott
Journal:  Circ Res       Date:  1983-11       Impact factor: 17.367

4.  Responses of human, monkey and dog coronary arteries in vitro to carbocyclic thromboxane A2 and vasodilators.

Authors:  N Toda
Journal:  Br J Pharmacol       Date:  1984-10       Impact factor: 8.739

5.  Influence of prostacyclin on regional blood flow distribution in anesthetized dogs.

Authors:  B A Schölkens; J Scholtholt; R Becker; W Jung; O Speth
Journal:  Arch Int Pharmacodyn Ther       Date:  1982-12

6.  Potentiation by ouabain of the response to vasoconstrictor agents of isolated dog cerebral and mesenteric arteries soaked in Ca2+-free media.

Authors:  N Toda
Journal:  J Cardiovasc Pharmacol       Date:  1982 May-Jun       Impact factor: 3.105

7.  The orally active thia-imino-prostacyclin Hoe 892: antiaggregatory and cardiovascular activities.

Authors:  B A Schölkens; D Gehring; W Jung
Journal:  Prostaglandins Leukot Med       Date:  1983-03

8.  Inhibition of platelet aggregation and reversal of vasopressin-induced ECG changes by a carboprostacyclin analogue, ONO 41483, in primates.

Authors:  P G Adaikan; S R Kottegoda; L C Lau; M Y Tai; S M Karim
Journal:  Prostaglandins Leukot Med       Date:  1982-09

9.  Carbacyclin--a potent stable prostacyclin analogue for the inhibition of platelet aggregation.

Authors:  B J Whittle; S Moncada; F Whiting; J R Vane
Journal:  Prostaglandins       Date:  1980-04

10.  Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation.

Authors:  A K Sim; A P McCraw; M E Cleland; S Nishio; T Umetsu
Journal:  Arzneimittelforschung       Date:  1985
View more
  19 in total

Review 1.  Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension.

Authors:  Ezequiel Balmori Melian; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Beraprost therapy in children with pulmonary hypertension secondary to congenital heart disease.

Authors:  A Limsuwan; P Pienvichit; P Khowsathit
Journal:  Pediatr Cardiol       Date:  2005 Nov-Dec       Impact factor: 1.655

3.  Beneficial effect of beraprost, a prostacyclin-mimetic agent, on post-hypoxic recovery of cardiac function and metabolism in rabbit isolated hearts.

Authors:  K Tanonaka; Y Maruyama; S Takeo
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

4.  Protective effect of beraprost sodium, a new chemically stable prostacyclin analogue, against the deterioration of baroreceptor reflex following transient global cerebral ischaemia in dogs.

Authors:  J Kurihara; T Sahara; H Kato
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

5.  Effects of beraprost on the transmembrane potentials of guinea-pig ventricular muscles during normoxia and hypoxia-reoxygenation.

Authors:  Y Ueno; K Shigenobu; S Nishio
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

6.  Suppression of pseudointimal hyperplasia by a novel prostacyclin analogue: beraprost.

Authors:  D I Kim; J Kambayashi; T Shibuya; M Sakon; T Kawasaki; T Mori
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

7.  Effects of beraprost sodium, a new prostaglandin I2 analog, on parameters of hemostasis, fibrinolysis, and myocardial ischemia in patients with exertional angina.

Authors:  K Sakata; T Hoshino; H Yoshida; T Kaburagi; A Takada
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

8.  Mechanisms of the biphasic responses to endothelin-3 in dog coronary arteries.

Authors:  T Okamura; T Matsumoto; F Ikemoto; N Toda
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

9.  Effects of antiplatelet agents and other factors on neointimal proliferation in iliac artery stenting: intravascular ultrasound analysis.

Authors:  Hisao Kumakura; Hiroyoshi Kanai; Yoshihiro Araki; Akira Koizumi; Shu Kasama; Hiroyuki Sumino; Shuichi Ichikawa
Journal:  Ann Vasc Dis       Date:  2009-12-14

10.  Use of prostaglandin I2 analog in treatment of massive hepatic necrosis associated with endothelial cell injury and diffuse sinusoidal fibrin deposition.

Authors:  K Fujiwara; S Mochida; A Ohno; M Arai; A Matsui; N Masaki; K Hirata; T Tomiya; M Yamaoka; S Nagoshi
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.